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Abstract: Some microbial species are chemically homogenous, and the same secondary 
metabolites are found in all strains. In contrast, we previously found that five strains of  
P. luteoviolacea were closely related by 16S rRNA gene sequence but produced two 
different antibiotic profiles. The purpose of the present study was to determine whether 
such bioactivity differences could be linked to genotypes allowing methods from 
phylogenetic analysis to aid in selection of strains for biodiscovery. Thirteen  
P. luteoviolacea strains divided into three chemotypes based on production of known 
antibiotics and four antibacterial profiles based on inhibition assays against Vibrio 
anguillarum and Staphylococcus aureus. To determine whether chemotype and inhibition 
profile are reflected by phylogenetic clustering we sequenced 16S rRNA, gyrB and recA 
genes. Clustering based on 16S rRNA gene sequences alone showed little correlation to 
chemotypes and inhibition profiles, while clustering based on concatenated 16S rRNA, 
gyrB, and recA gene sequences resulted in three clusters, two of which uniformly consisted 
of strains of identical chemotype and inhibition profile. A major time sink in natural 
products discovery is the effort spent rediscovering known compounds, and this study 
indicates that phylogeny clustering of bioactive species has the potential to be a useful 
dereplication tool in biodiscovery efforts.  
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1. Introduction 
Many antibiotics used in treatment of infectious disease are of natural product origin, and despite 
high hopes for new drug discovery strategies, alternative approaches to drug discovery such as 
combinatorial chemistry has failed to adequately supply the drug pipeline [1]. Therefore, we must 
revert to discovery of novel natural products capable of inhibiting or killing pathogenic bacteria [2], 
and screening of microorganisms [3] from extreme or underexplored environments [4] could be a 
promising approach. The marine environment is still considered an underexplored source of novel 
antimicrobial compounds and marine microorganisms are viewed as a potential source of novel 
antibiotic compounds [5–7]. Indeed, marine bacteria belonging to the Cyanobacteria [8], 
Actinobacteria [9], the Roseobacter clade [10,11], and the Pseudoalteromonas genus [12,13] produce 
compounds with interesting pharmacological properties.  
Members of the genus Pseudoalteromonas are ubiquitous in the marine environment [14] and form 
two groups supported by analysis of 16S rRNA gene sequences [15]. One group predominantly 
consists of non-pigmented pelagic bacteria with low or no antibacterial activity while most species in 
the other group are pigmented, antagonistic, and found as colonizers marine biotic surfaces, thus 
pigmented Pseudoalteromonads represent a promising target for biodiscovery efforts. 
One of the main challenges in natural products discovery is the effort squandered rediscovering 
known compounds [16], hence so called ―dereplication‖ strategies to reduce the degree of rediscovery 
prior to purification of compounds and structure elucidation steps are of outmost importance [17–19]. 
One such strategy is early stage dereplication informed by microbial systematics [20–22]. Some 
bacterial species are chemically very homogeneous and all strains produce the same biologically active 
secondary metabolites as is seen for production of tropodithietic acid in Phaeobacter gallaeciencis or 
Ruegeria mobilis [23] or salinisporamide A in Salinispora tropica [24]. This makes early dereplication 
of such strains of high value in biodiscovery to reduce discoveries of one compound from several 
strains. Add to this that novel bacterial diversity likely also represents a reservoir for novel chemistry 
and it is clear why bacterial systematics may play a role in natural product discovery. Indeed, 
Goodfellow and Fiedler [25] recently pointed out that screening of a taxonomically dereplicated 
collection of Actinobacteria led to discovery of a high number of novel compounds relative to the 
strain throughput. Hence, it may be possible to apply knowledge of bacterial systematics and 
taxonomy as a guide for efficient biodiscovery within bacteria. We previously reported [26] that five 
Pseudoalteromonas luteoviolacea strains with nearly identical 16S rRNA gene sequences produced 
two combinations of the three antibacterial compounds violacein [27], indolmycin [28], and 
pentabromopseudilin [29]. Hence, P. luteoviolacea was suitable for investigating relations between 
bacterial systematics and production of bioactive secondary metabolites at the infra-species level. 
  
Mar. Drugs 2012, 10  
 
 
1731 
The aim of the present study was to determine if strain differences in production of antibacterial 
compounds by Pseudoalteromonas luteoviolacea were linked to systematic groups which may point to 
phylogenetic analyses as a tool in biodiscovery. 16S rRNA, gyrB, and recA genes of 13 P. luteoviolacea 
strains were sequenced and used in sub-typing. Coupled with information on antibiosis obtained from 
agar based inhibition assays, we found that the combination of screening for inhibition and sub-typing 
by phylogenetic analysis would allow selection of representative bioactive strains within this  
collection of P. luteoviolacea strains and hence could represent an approach for dereplication of 
Pseudoalteromonas strains in small-molecule biodiscovery programs. 
2. Results and Discussion 
2.1. Pseudoalteromonas luteoviolacea Production of Antibacterial Compounds and Antibacterial Activity 
All 13 strains produced the purple antibacterial pigment, violacein (Table 1). Five strains produced 
pentabromopseudilin (chemotype 1), three strains produced indolmycin (chemotype 2) and four strains 
did not produce other known antibiotics (chemotype 3). No strain produced both indolmycin and 
pentabromopseudilin. Hence, the sub-division previously seen with respect to pentabromopseudilin 
and indolmycin was confirmed in a larger selection of strains. We have attempted to further broaden 
our collection; however, we were unable to do so as P. luteoviolacea under certain conditions is 
autoinhibitory [30] and several laboratories no longer had stock cultures.  
Despite the violacein production by all strains, just 11 of the 13 strains inhibited V. anguillarum and 
S. aureus in the live cell assay (Table 1). This indicates that violacein is not a major antibacterial 
compound under these conditions. Instead, violacein has been suggested to act as a cell-associated 
anti-predation compound [31] which is more in line with its low solubility in water and distinct  
cell-association and offers an ecological role for this compound which may explain the ubiquitous 
production within strains of P. luteoviolacea. Sterile filtered culture supernatants were tested in well 
diffusion agar assays. Sterile filtered supernatants were antibacterial only if harvested from strains 
producing either pentabromopseudilin (6 strains, inhibition profile A) or indolmycin (3 strains, 
inhibition profile B). Both indolmycin and pentabromopseudilin containing supernatants inhibited  
S. aureus, whereas only indolmycin containing supernatants inhibited the Gram-negative V. anguillarum 
(Table 1). This is in agreement with previous studies describing pentabromopseudilin as a compound 
targeting Gram-positive bacteria, whereas indolmycin, previously only isolated from Streptomyces 
species [32,33], inhibits both Gram-positive and Gram-negative bacteria and is very potent against 
staphylococci [34]. The supernatants from the remaining four strains were not inhibitory against either 
of the target organisms and these four strains produced neither indolmycin nor pentabromopseudilin. 
Discrepancies among live cell and sterile supernatant inhibition profiles (inhibition profile C) suggest 
that additional antibiotic compounds may be produced, for instance macromolecular antibiotics such as 
L-amino acid oxidases which are produced by some P. luteoviolacea strains [35].  
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Table 1. Inhibitory activity of P. luteoviolacea strains in the live cell and sterile filtered supernatant well diffusion agar assays and production 
of three known antibacterial compounds (PBP = pentabromopseudilin) in marine minimal medium cultures. The production of antibacterial 
compounds was determined by qualitative LC-MS analysis. V. ang. = Vibrio anguillarum; x: Inhibition or compound production, respectively; 
-: No inhibition or compound production. 
 Live cell inhibition 
 
Supernatant inhibition 
 
Antibacterial compounds produced 
 
 Inhibition 
profile 
Genotype * 
Strain V. ang. S. aureus V. ang. S. aureus Violacein PBP Indolmycin Chemotype 
2ta16 x x  - x  x x -  1 A I 
NCIMB 1944 x x  - x  x x -  1 A I 
DSM6061 
T
 x x  - x  x x -  1 A I 
CPMOR-2 x x  - x  x x -  1 A I 
S2607 x x  - x  x x -  1 A III 
S4060-1 x x  - x  x x -  1 A III 
S4047-1 x x  x x  x - x  2 B II 
S4054 WT x x  x x  x - x  2 B II 
CPMOR-1 x x  x x  x - x  2 B II 
H33 x x  - -  x - -  3 C III 
H33S x x  - -  x - -  3 C III 
NCIMB 1942 - -  - -  x - -  3 D III 
NCIMB 2035 - -  - -  x - -  3 D III 
* Please refer to the second figure in the manuscript. 
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2.2. Clustering of P. luteoviolacea Strains in Genotypes 
Phylogenetic trees were created based on 16S rRNA gene sequences alone or concatenated 16S 
rRNA, gyrB, and recA gene sequences. The 16S rRNA sequences were identical at a level of >99% 
and the phylogenetic reconstruction showed no correlation to production of antibiotics within clusters 
(Figure 1). The resolving power of the 16S rRNA gene is limited when performing phylogenetic 
analyses below the species level [36] whereas studies have shown the usefulness of housekeeping 
genes such as recA and gyrB [37–39] in resolving sub-species phylogenetic relations. Seperate 
analyses of recA and gyrB genes were carried out to verify that each gene contributed to phylogenetic 
delineation (data not shown). 
Figure 1. Clustering of 13 P. luteoviolacea strains by 16S rRNA gene sequence analysis in 
MEGA5. Bootstrap values are based on 1000 resamplings. Square: pentabromopseudilin 
producer, circle: indolmycin producer. All strains produced violacein. Scale bar: 
substitutions per site. 
 
A phylogenetic analysis of concatenated 16S rRNA, gyrB and recA genes led to identification of 
three clusters (Figure 2) as indicated in Table 1 under genotypes. Genotype I represents 4 of the  
6 pentabromopseudilin producing strains of chemotype 1 and inhibition profile A. Genotype II is 
identical to chemotype 2 and inhibition profile B. Genotype III is heterogeneous, covering two strains 
of chemotype 1 with inhibition profile A, two strains of chemotype 3 with inhibition profile C and two 
strains of chemotype 3 with inhibition profile D. Within genotype III, sub-clusters tightly reflected 
associations to chemotype and inhibition profile.  
A correlation among taxonomic units and secondary metabolite synthesis is well established in the 
world of fungal natural products [40], and was also seen among marine actinomycete Salinispora spp. 
Indeed, within actinobacteria bacterial systematics are emerging as a tool to aid in biodiscovery by 
focusing on the use of bacterial systematics to dereplicate actinobacterial species in order to focus on 
novel diversity and its potential for novel chemistry. To our knowledge, this approach has not been 
tested within the γ-Proteobacteria, or at the infraspecies level within a group of closely related strains 
as presented here for P. luteoviolacea. 
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Figure 2. Clustering of concatenated 16S rRNA, gyrB and recA nucleotide sequences  
of 13 P. luteoviolacea strains analyzed in MEGA5. Bootstrap values are based on  
1000 resamplings. The topology was supported by the maximum parsimony method  
(data not shown). Square: pentabromopseudilin producer, circle: indolmycin producer. All 
strains produced violacein. Scale bar: substitutions per site. 
 
2.3. MIC of Known Antagonistic Compounds 
To investigate the potential role of indolmycin and violacein as antibacterial compounds, the  
MICs against V. anguillarum, S. aureus, and the 13 P. luteovioloacea strains were determined. 
Pentabromopseudilin was not included as the compound was unavailable as commercial reference 
standard. Under the experimental conditions in this study violacein did not inhibit any of the included 
strains at tested concentrations; hence the MIC of violacein for all tested strains was >128 μg/mL. This 
is in agreement with the lack of inhibition observed in some violacein producing strains (Table 1). The 
MIC of indolmycin to V. anguillarum was 2 μg/mL whereas S. aureus was inhibited by indolmycin at 
all tested concentrations, resulting in a MIC of ≤0.5 μg/mL. None of the P. luteoviolaceae, irrespective of 
antibiotic profile, were inhibited by indolmycin leading to a MIC of >128 µg/mL.  
Biosynthetic pathways are subjects of horizontal gene transfer events and their organization in 
genetic clusters facilitates the exchange of entire biological pathways among bacterial strains [41–43]. 
This intuitively supports the common expectation that secondary metabolite production is strain 
specific [44] and hence bacterial systematics would not be expected to be related to the secondary 
metabolome. In contrast, distinct species-specific secondary metabolite profiles were observed within 
the genus Salinispora and it was suggested that biosynthetic gene clusters are stably maintained in 
these species due to the distinct competitive advantage obtained through antibiosis and may in fact 
represent niche-specific adaptations [45]. Further studies of the biosynthetic pathways behind the 
antibiotic production of P. luteoviolacea and their genomic context are likely to add to our 
understanding of these concepts.  
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3. Experimental Section  
3.1. Bacterial Strains and Culture Conditions 
Thirteen P. luteoviolacea strains were used in this study (Table 2). They originated from distinct 
geographical areas and were primarily isolated from surface water or algae. The strains were cultured 
in a marine minimal medium (MMM) [46] with 4 g/L mannose and 3 g/L casamino acids. All strains 
were incubated at 25 °C and 200 rpm agitation. 
Table 2. P. luteoviolacea strains used in this study. The phylogenetic position of all strains 
within the Pseudoalteromonas luteoviolacea clade was verified by analysis of partial 16S 
rRNA gene sequences (>1200 bp). 
Strain name Origin Source 
DSM 6061 
T
 Mediterranean, Nice Surface water 
S2607 Pacific, Eastern Australia Rock surface 
S4060-1 Pacific, Costa Rica Seaweed 
2ta16 Florida Keys, USA M. annularis coral 
CPMOR-2 Mediterranian, Murcia Surface water 
NCIMB1944 Mediterranean, Nice Surface water 
S4047-1 Pacific, Costa Rica Seaweed 
S4054 Pacific, Costa Rica Seaweed 
CPMOR-1 Mediterranean, Murcia Macroalgae 
H33 Sydney, Australia Unknown 
H33S Sydney, Australia Unknown 
NCIMB1942 Mediterranean, Nice Surface water 
NCIMB2035 Mediterranean, Nice Surface water 
3.2. Assays for Inhibition of Bacterial Growth  
Vibrio anguillarum 90-11-287 [47] and Staphyloccoccus aureus 8325 were cultured in tryptic soy 
broth (Difco, USA). Well diffusion agar assays were carried out as previously described. The assay 
substrate contained 30 g/L Sea Salts (Sigma, USA) and 10 g/L agar. To support growth of  
V. anguillarum 4 g/L glucose and 3 g/L casamino acids was added. An additional 5 g/L peptone was 
added to S. aureus agar. Antibiosis by live cells was tested by spotting colony mass directly onto the 
assay plates and observing if clearing zones had formed following incubation for 24 h.  
3.3. Analytical Detection of Antibacterial Compounds  
Samples for LC-MS analyses were prepared from cultures in MMM extracted with ethyl acetate 
(EtOAc). Extracts were dried under nitrogen and redissolved in methanol (MeOH). LC-MS samples 
were analysed using an Agilent 1100 HPLC system with a diode array detector (Waldbronn, Germany) 
coupled to an LCT TOF mass spectrometer (Micromass, Manchester, UK) using a Z-spray 
electrospray (ESI) source. A Phenomenex Luna II C18 column (50 mm × 2 mm, 3 μm) was used for 
separation, applying a linear acetonitrile (MeCN)-water (20 mM formic acid) 0.3 mL∙min−1 gradient 
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(15%–100%) over 20 min at 40 °C. For all LC-MS analyses, violacein and indolmycin were detected 
in positive ionisation mode (ESI
+
), while pentabromopseudilin was detected in negative mode (ESI
−
). 
3.4. PCR Amplification and Sequencing  
DNA was purified from overnight P. luteoviolacea cultures using the NucleoSpin Tissue kit 
(Machery-Nagel, Germany) or QIAGEN Genomic-Tip G/100 (QIAGEN, USA) following the 
manufacturer’s protocol. 16S rRNA genes from strains H33, H33S, NCIMB 1942, NCIMB 1944 and 
NCIMB 2035 and gyrB and recA genes from all strains were amplified by PCR. One reaction 
consisted of 2.5 µL 10× Hot Start PCR buffer (Fermentas, Canada), 2.5 µL 2 mM dNTP mix, 4 µL  
25 mM MgCl2, 0.8 µL 12.5 µM forward primer, 0.8 µL 12.5 µM reverse primer, 12.28 µL MilliQ H2O, 
0.2 µL Maxima Hot Start Taq DNA polymerase (Fermentas, Canada) and 1 µL DNA template at  
50 ng/µL for a total volume of 25 µL. The reactions were performed on an Applied Biosystems Veriti 
96 well cycler. 16S rRNA genes were amplified according to. The primers and reaction conditions 
used for gyrB amplification were as described in [48]. Primers and conditions for amplification of recA 
fragments were according to [49]. Sequencing was done by Eurofins MWG Operon, Germany. 
Nucleotide sequences generated in this study were deposited in GenBank under accession numbers: 
16S rRNA JQ250820-JQ250824, gyrB JQ280430-JQ280442 and recA JQ280417-JQ280429. 
Accession numbers for 16S rRNA nucleotide sequences previously available from GenBank: 
NR_026221, FJ457234, FJ457187, FJ457230, FJ457238, EU158365, EU158366 and FJ952782. 
3.5. Phylogenetic Analysis 
Analysis of concatenated gene sequences, termed multi locus sequence analysis, has succesfully 
been used to infer robust phylogenies within, e.g., the Vibrionaceae [49], and a similar approach was 
used in this study. The 16S rRNA gene sequences were obtained from GenBank or by sequencing and 
aligned in MEGA5 using MUSCLE [50]. The evolutionary history was inferred using the maximum 
likelihood method based on the Kimura 2-parameter model [51]. The phylogenetic tree was 
constructed using MEGA5 default settings. For analysis of recA and gyrB sequences, an alignment was 
created for each gene in MEGA5 using MUSCLE. The alignments were curated manually and 
trimmed to be of equal length and in-frame. 16S rRNA, gyrB and recA alignments were concatenated 
and phylogenetic analyses were performed in MEGA5. Evolutionary relationships based on the 
nucleotide sequences were inferred using the maximum likelihood method with the general time 
reversible model [52], assuming a gamma distributed substitution rate with five discrete categories. 
Neighbor-joining phylogenetic trees were generated and tested with 1000 bootstrap replications.  
3.6. Minimum Inhibitory Concentrations (MIC) of Violacein and Indolmycin 
MICs of commercially available violacein (Sigma, USA) and indolmycin (Bioaustralis, Australia) 
standards to P. luteoviolacea strains, V. anguillarum 90-11-287, and S. aureus 8325 were tested. MIC 
assays were carried out in 96-well microtiter plates according to the guidelines by the clinical and 
laboratory standards institute [53], with minor modifications. P. luteoviolacea was cultured in MMM 
with 4 g/L mannose and 3 g/L casamino acids, V. anguillarum in MMM with 4 g/L glucose and  
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3 g/L casamino acids, and S. aureus in MHB. Overnight bacterial cultures were diluted to 10
5
 CFU/mL 
and 90 µL added per well. 10 µL of antibiotic solution was added to each well. The antibiotics were 
tested in serial two-fold dilutions at final concentrations of 0.5 µg/mL to 128 µg/mL. Controls were 
included for no antibiotic and ethanol solvent. The well containing the lowest concentration of 
antibiotic that had no visual bacterial growth after 48 h corresponded to the MIC. 
4. Conclusions  
In summary, combining simple inhibitory screening and information on gene based sub-types 
allows a targeted biological dereplication of P. luteoviolacea strains before chemical analysis of 
secondary metabolite production. This approach potentially enables selection of key strains and a 
reduction of the bottle neck and expenses associated with screening of large collections of  
non-dereplicated bacterial strains.  
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